The FDA Contacted 2,200+ Sponsors on Trial Results: What You Need to Know

What’s new

On March 30, the US Food and Drug Administration (FDA) sent messages (press release) to more than 2,200 companies and researchers tied to over 3,000 registered clinical trials (including some that were publicly funded), reminding them to submit required results to ClinicalTrials.gov or complete the National Library of Medicine (NLM) quality control (QC) review process. Under federal law, sponsors of applicable clinical trials must submit results within one year of the trial’s primary completion date. An internal analysis found that 29.6% of applicable studies have no results submitted. Applicable studies are interventional trials with a US nexus involving an FDA-regulated product, excluding Phase I and device feasibility studies.

Why it matters

• This is a blanket reminder, not a targeted enforcement action. The criteria appear to have swept in studies with valid delay certifications or results still in QC review, so receiving a message does not necessarily mean you are out of compliance.
• Still, the 29.6% non-reporting rate is significant.
• The FDA is framing this as an opportunity to comply voluntarily before the agency moves to Pre-Notices or Notices of Noncompliance.
• The tone is cooperative, but the enforcement infrastructure is real: Under the US Food and Drug Administration Amendments Act (FDAAA) 801 and the US Code of Federal Regulations’ 42 CFR Part 11, the FDA has authority to impose civil monetary penalties of up to $10,000 per day for noncompliance.

What’s next/who’s impacted

Sponsors and investigators who received messages should not assume it reflects an error on the FDA’s part. Regulatory affairs or clinical operations teams should confirm status across your portfolio. Specifically:

• Verify that delay certifications are current.
• Confirm QC review status with NLM.
• Review results submission timelines against primary completion dates.

For those who are out of compliance, the window to act voluntarily is open, but it may not stay open indefinitely. If you identify gaps, submit results directly to ClinicalTrials.gov.

For everyone else, this is a clear signal that the FDA is actively monitoring the results gap. FDA Commissioner Marty Makary specifically called out suppression of unfavorable results as a priority.

The bottom line

This round is voluntary outreach, not formal enforcement. But the escalation path is clear:

• Reminder (this step)
• Pre-Notice of Noncompliance
• Formal Notice of Noncompliance
• Civil monetary penalties

If you received a message, confirm whether you have outstanding results due. Given the broad criteria, this may be more of a friendly reminder than a flag.

If you didn’t receive one, review your portfolio anyway.